Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cisplatin + rintatolimod + interferon alpha + celecoxib + alpha-type-1-polarized dendritic cell vaccine
- Development stage
- Unknown
- Lead developer
- UPMC Hillman Cancer Center
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Intraperitoneal, Oral, Intradermal, Intranodal
01
Overview
Cisplatin + CKM + celecoxib + DC vaccine is an investigational chemo-immunotherapy combination regimen developed by the Roswell Park Comprehensive Cancer Center for the treatment of advanced-stage ovarian cancer. The regimen is designed to reprogram the tumor microenvironment (TME) from an immunosuppressive state to one that favors the infiltration and activity of cytotoxic T lymphocytes (CTLs). It consists of four primary components: intraperitoneal cisplatin (a DNA-alkylating chemotherapy), a chemokine modulatory (CKM) regimen comprising rintatolimod (a TLR3 agonist) and interferon-alpha (IFNα), oral celecoxib (a COX-2 inhibitor), and an autologous alpha-type-1-polarized dendritic cell (alpha-DC1) vaccine. By combining these agents, the therapy aims to increase the production of CTL-attracting chemokines (such as CXCL9 and CXCL10) while suppressing regulatory T cell (Treg)-attracting signals (such as CCL22) and prostaglandin E2 (PGE2) production. This multi-pronged approach is currently being evaluated in Phase 1/2 clinical trials for patients with recurrent or advanced ovarian cancer.
- Other names
- cisplatin + CKM + celecoxib + DC vaccineIPC-CKM + alphaDC1 vaccinecisplatin + CKM + celecoxib + alpha-DC1 vaccine
02
Targets
PTGS2 (Prostaglandin-Endoperoxide Synthase 2)DNAIFNAR (Immune system modulation via type I interferon receptor)IFNAR2 (Interferon alpha/beta receptor subunit 2)TLR3 (Toll-like receptor 3)
Beyond the preview
Go deeper on cisplatin + rintatolimod + interferon alpha + celecoxib + alpha-type-1-polarized dendritic cell vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cisplatin + rintatolimod + interferon alpha + celecoxib + alpha-type-1-polarized dendritic cell vaccine.